Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 1.5%

Lexeo Therapeutics, Inc. (NASDAQ:LXEO)’s share price fell 1.5% during mid-day trading on Thursday . The stock traded as low as $11.57 and last traded at $12.07. 83,451 shares changed hands during mid-day trading, a decline of 19% from the average session volume of 102,474 shares. The stock had previously closed at $12.26.

Lexeo Therapeutics Price Performance

The firm has a 50 day simple moving average of $14.62. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Monday, March 11th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.15). Research analysts expect that Lexeo Therapeutics, Inc. will post -3.03 EPS for the current year.

Institutional Investors Weigh In On Lexeo Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $202,000. Barclays PLC bought a new position in Lexeo Therapeutics in the fourth quarter worth $208,000. Northern Trust Corp bought a new position in Lexeo Therapeutics in the fourth quarter worth $209,000. Cubist Systematic Strategies LLC bought a new position in Lexeo Therapeutics in the fourth quarter worth $346,000. Finally, Verition Fund Management LLC bought a new position in Lexeo Therapeutics in the fourth quarter worth $2,537,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.